 |
|
Older liver donors not associated with negative outcomes in transplant recipients with hepatitis C
July 22, 2008Receiving a liver from a donor older than age 60 does not appear to be associated with transplant failure, death or recurrent disease in the next five years among transplant patients with the hepatitis C virus, according to a report in the July issue of Archives of Surgery, one of the JAMA/Archives journals.
Hepatitis C virus infection is the most common cause of the liver disease cirrhosis and the most common indication for liver transplant for U.S. adults, according to background information in the article. Currently, about 17,000 patients are on the waiting list for a liver transplant. Many medical centers have expanded donor criteria, including increasing age limits, to increase the pool of available organs. "There are concerning reports, however, in recipients with hepatitis C virus that extended criteria donors, particularly older donors, are associated with poorer outcome, especially with early and severe hepatitis C virus recurrence in the donor graft," the authors write.
M.B. Majella Doyle, M.D., and colleagues at Washington University School of Medicine, St. Louis, analyzed data from 489 adult liver transplants performed at the school between 1997 and 2006. Of these patients, 187 (38.2 percent) were infected with the hepatitis C virus and 302 (61.8 percent) had other indications for liver transplant.
Of patients with the hepatitis C virus, 88.1 percent were alive after one year, 78.3 percent survived three years and 69.2 percent survived five years. Donor livers were still functioning in 85.6 percent of hepatitis C virus-positive recipients after one year, 75.6 percent after three years and 65.6 percent after five years. There were no differences in rates of survival and graft (organ) survival between patients with and without hepatitis C in the short or medium term (at one, three or five years). "However, similar to other long-term transplant centers, we observed a negative effect from recurrent hepatitis C virus with a trend toward worsened long-term survival between years five and 10," the authors write.
A total of 72 patients received organs from donors age 60 and older, including 24 (12.8 percent) with hepatitis C virus and 48 (15.9 percent) without the virus. There were no differences in one-, three- or five-year patient or graft survival rates when these patients-or those who received organs from donors age 65 and older-were compared with those who received organs from younger donors. Because the use of older donors has primarily occurred in the past five years, long-term comparisons were not possible. However, the early results suggest the practice is safe, the authors note.
"In conclusion, overall patient and graft survival in hepatitis C virus-positive recipients is comparable with that in hepatitis C virus-negative patients, and there seems to be little, if any, adverse effect on short- and medium-term follow-up with the use of carefully selected older donor grafts in recipients with hepatitis C virus," they conclude. "Data from this series suggest that the continued use of selected older donors is a safe method of expanding the liver donor pool, even for hepatitis C-positive recipients."
JAMA and Archives Journals
Of patients with the hepatitis C virus, 88.1 percent were alive after one year, 78.3 percent survived three years and 69.2 percent survived five years. Donor livers were still functioning in 85.6 percent of hepatitis C virus-positive recipients after one year, 75.6 percent after three years and 65.6 percent after five years. There were no differences in rates of survival and graft (organ) survival between patients with and without hepatitis C in the short or medium term (at one, three or five years). "However, similar to other long-term transplant centers, we observed a negative effect from recurrent hepatitis C virus with a trend toward worsened long-term survival between years five and 10," the authors write.
A total of 72 patients received organs from donors age 60 and older, including 24 (12.8 percent) with hepatitis C virus and 48 (15.9 percent) without the virus. There were no differences in one-, three- or five-year patient or graft survival rates when these patients-or those who received organs from donors age 65 and older-were compared with those who received organs from younger donors. Because the use of older donors has primarily occurred in the past five years, long-term comparisons were not possible. However, the early results suggest the practice is safe, the authors note.
"In conclusion, overall patient and graft survival in hepatitis C virus-positive recipients is comparable with that in hepatitis C virus-negative patients, and there seems to be little, if any, adverse effect on short- and medium-term follow-up with the use of carefully selected older donor grafts in recipients with hepatitis C virus," they conclude. "Data from this series suggest that the continued use of selected older donors is a safe method of expanding the liver donor pool, even for hepatitis C-positive recipients."
JAMA and Archives Journals
Hepatitis News and Current Hepatitis Events RSSEarly trigger for type-1 diabetes found in mice, Stanford scientists report
Scientists at the Stanford University School of Medicine are shedding light on how type-1 diabetes begins.
To protect against liver disease, body puts cells 'under arrest'
A stable form of cell-cycle arrest known to offer potent protection against cancer also limits liver fibrosis, a condition characterized by an excess of fibrous tissue, according to a new report in the August 22nd Cell, a Cell Press publication.
Senescence in liver cells is found by CSHL scientists to help limit acute tissue damage
Although post-reproductive life in humans is often associated with decline and a loss of powers, an analogous state in certain cells -- called senescence -- is proving to be one of ironic potency. Scientists at Cold Spring Harbor Laboratory (CSHL) today reported that a particular class of senescent liver cells orchestrates a sequence of events in living mice that can limit fibrosis, a natural response of the liver to acute damage.
Trapping white blood cells proves novel strategy against chronic viral infections
Seeing disease-fighting white blood cells vanish from the blood usually signals a weakened immune system. But preventing white blood cells' circulation by trapping them in the lymph nodes can help mice get rid of a chronic viral infection, researchers at Yerkes National Primate Research Center and the Emory Vaccine Center have found.
Trapping white blood cells proves novel strategy against chronic viral infections
Seeing disease-fighting white blood cells vanish from the blood usually signals a weakened immune system. But preventing white blood cells' circulation by trapping them in the lymph nodes can help mice get rid of a chronic viral infection, researchers at Yerkes National Primate Research Center and the Emory Vaccine Center have found.
Nano vaccine for hepatitis B shows promise for third world
Chronic hepatitis B infects 400 million people worldwide, many of them children. Even with three effective vaccines available, hepatitis B remains a stubborn, unrelenting health problem, especially in Africa and other developing areas.
Early treatment is key to combating hepatitis C virus
Canadian researchers have shown that patients who receive early treatment for Hepatitis C virus (HCV) within the first months following an infection, develop a rapid poly-functional immune response against HCV similar to when infection is erradicted spontaneously, according to a new study published in the Journal of Virology.
International panel updates treatment guidelines for HIV infection
An evaluation of recent data has led to an update in the guidelines and recommendations for antiretroviral treatment of adult human immunodeficiency virus (HIV) infection, according to an article in the August 6 issue of JAMA, a theme issue on HIV/AIDS.
Imiquimod, an immune response modifier, is dependent on the OGF-OGFr signaling pathway
Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered that the efficacy of imiquimod, a clinically important immune response modifier with potent antiviral and antitumor activity, is dependent on the Opioid Growth Factor (OGF)-OGF receptor (OGFr) axis for its action.
Researchers disprove long-standing belief about HIV treatment
Researchers at Wake Forest University Baptist Medical Center have disproved a long-standing clinical belief that the hepatitis C virus slows or stunts the immune system's ability to restore itself after HIV patients are treated with a combination of drugs known as the "cocktail."
More Hepatitis News Articles
 | Dr. Melissa Palmer's Guide To Hepatitis and Liver Disease by Melissa Palmer In the United States alone, more than four million people are infected with the hepatitis C virus, and chronic liver disease is the twelfth leading cause of death. In this revised and updated edition of her groundbreaking 2000 book, renowned hepatologist Dr. Melissa Palmer discusses all facets of liver disease, from symptoms and tests to treatment options and lifestyle changes. In addition, this... |
 | Herbs for Hepatitis C and the Liver (A Storey Medicinal Herb Guide) by Stephen Harrod Buhner An insightful overview of the impending Hepatitis C epidemic, its causes, the most recent research, and an in-depth, detailed look at the botanical medicines that show promising results for restoring liver function. Includes formulas for using herbs to strengthen the liver and combat... |
 | Hepatitis C Cookbook: Easy and Delicious Recipes by Heather Jeanne Hepatitis C is a potentially fatal virus that attacks the liver. According to the Centers for Disease Control, Hepatitis C has already infected an estimated four to five million Americans, and worldwide it may have infected as many as 200 million. Most experts agree that if the rate of Hepatitis C infection isn't curbed soon, it will eventually kill more people each year than AIDS. However,... |
 | Living With Hepatitis C For Dummies by Nina L. Paul A comprehensive, empathetic guide for anyone suffering from this serious liver disease Approximately 4 million Americans and 170 million people worldwide suffer from hepatitis C, a viral liver disease that is treatable but not curable. It accounts for more than 40 percent of U.S. liver disease deaths-about 8,000 to 10,000 people annually-and is the most common reason for liver transplantation.... |
 | Living with Hepatitis C: A Survivor's Guide, Fourth Edition (Living with) by Gregory T. Everson, Hedy Weinberg "An extremely useful title…recommended."—Library JournalLiving with Hepatitis C was the first book to explain in everyday language the causes of the disease, the major and minor symptoms, and all of the latest treatments, including pegylated interferons. Since its first publication, researchers have made dramatic strides in helping the millions of Americans who suffer from this deadly... |
 | The Hepatitis C Help Book, Revised Edition: A Groundbreaking Treatment Program Combining Western and Eastern Medicine for Maximum Wellness and Healing by Misha Ruth Cohen, Robert Gish, Kalia Doner A fully updated and revised edition of an important health guide, including the latest information on optimum interferon protocol. Hepatitis C has been called "the emergent and preeminent public-health problem of the twenty-first century--surpassing HIV." It has also been dubbed "The Shadow Epidemic," because it is one of the most clandestine of viruses and infects healthy people who have no idea... |
 | Triumph Over Hepatitis C : An Alternative Medicine Solution Revised Edition by Lloyd Wright A graphic, turbo charged saga, depicting actual events in the life of Lloyd Wright, as he struggled with the menace, Hepatitis C. gue of Bicyclists Mr. Wright describes how American doctors deal with Hepatitis C, there lack of knowledge and education about life saving and immune system boosting herbs, supplements and foods. This is a true life journy from infection to being at "Death's Door",... |
 | The Hepatitis C Handbook by Matthew Dolan This definitive guide explains clearly what Hepatitis C is, outlines the course of the disease and the associated symptoms, and describes how it is transmitted. The author discusses available treatments as well as lifestyle changes that may help. Extensive sections on herbs, vitamins, and nutritional supplements are also... |
 | Healing Hepatitis Naturally (Doctors' Prescription for Healthy Living) If you're suffering from hepatits... If you don't know where to turn to enhance your body's healing response and your doctor's conventional treatments are not helping as much as you expected... Healing Hepatitis Naturally is an indispensable resource. Learn how: Herbal formulas support overall wellbeing, normalize liver enzymes and support viral clearance in cases of hepatitis. Systemic oral... |
 | Basic Infection Control for Healthcare Providers by Michael Kennamer Basic Infection Control for Health Care Providers, Second Edition, is a clear and concise guide to preventing occupational exposure hazards and communicable and infectious diseases. This book includes coverage on how to safely protect oneself from infectious agents and what do in case of infectious exposure. Discussions of the disease process and legal issues surrounding exposure and infectious... |
| © 2008 BrightSurf.com |